Free Trial
→ Why I'm selling my Snapback Indicator for just $7 (From Base Camp Trading) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alvotech stock logo
ALVOW
Alvotech
$0.20
+42.5%		$0.32
$0.12
▼
$1.05
N/AN/A4,526 shs2,210 shs
Apollomics, Inc. stock logo
APLMW
Apollomics
$0.01
$0.01
$0.01
▼
$0.23
N/AN/A49,946 shs1,000 shs
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
$0.21
+40.8%		$0.31
$0.05
▼
$0.98
N/AN/A4,682 shs605 shs
TFF Pharmaceuticals, Inc. stock logo
TFFP
TFF Pharmaceuticals
$0.07
$0.06
$0.06
▼
$3.23
N/AN/AN/AN/A
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alvotech stock logo
ALVOW
Alvotech
-22.00%+0.29%-68.77%-26.18%-84.66%
Apollomics, Inc. stock logo
APLMW
Apollomics
0.00%-15.00%+0.99%-43.33%-47.15%
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
+19.39%-19.26%-34.33%+165.86%-25.38%
TFF Pharmaceuticals, Inc. stock logo
TFFP
TFF Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alvotech stock logo
ALVOW
Alvotech
$0.20
+42.5%		$0.32
$0.12
▼
$1.05
N/AN/A4,526 shs2,210 shs
Apollomics, Inc. stock logo
APLMW
Apollomics
$0.01
$0.01
$0.01
▼
$0.23
N/AN/A49,946 shs1,000 shs
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
$0.21
+40.8%		$0.31
$0.05
▼
$0.98
N/AN/A4,682 shs605 shs
TFF Pharmaceuticals, Inc. stock logo
TFFP
TFF Pharmaceuticals
$0.07
$0.06
$0.06
▼
$3.23
N/AN/AN/AN/A
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alvotech stock logo
ALVOW
Alvotech
-22.00%+0.29%-68.77%-26.18%-84.66%
Apollomics, Inc. stock logo
APLMW
Apollomics
0.00%-15.00%+0.99%-43.33%-47.15%
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
+19.39%-19.26%-34.33%+165.86%-25.38%
TFF Pharmaceuticals, Inc. stock logo
TFFP
TFF Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alvotech stock logo
ALVOW
Alvotech
0.00
N/AN/AN/A
Apollomics, Inc. stock logo
APLMW
Apollomics
0.00
N/AN/AN/A
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
0.00
N/AN/AN/A
TFF Pharmaceuticals, Inc. stock logo
TFFP
TFF Pharmaceuticals
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alvotech stock logo
ALVOW
Alvotech
$491.95MN/AN/AN/AN/AN/A
Apollomics, Inc. stock logo
APLMW
Apollomics
N/AN/AN/AN/AN/AN/A
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
$5.85MN/AN/AN/AN/AN/A
TFF Pharmaceuticals, Inc. stock logo
TFFP
TFF Pharmaceuticals
$730K0.40N/AN/AN/A∞
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alvotech stock logo
ALVOW
Alvotech
N/AN/AN/AN/AN/AN/AN/AN/AN/A
Apollomics, Inc. stock logo
APLMW
Apollomics
N/AN/AN/AN/AN/AN/AN/AN/AN/A
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
N/AN/AN/AN/AN/AN/AN/AN/A11/18/2026 (Estimated)
TFF Pharmaceuticals, Inc. stock logo
TFFP
TFF Pharmaceuticals
-$21.24M-$6.44N/AN/AN/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Alvotech stock logo
ALVOW
Alvotech
N/AN/AN/AN/AN/A
Apollomics, Inc. stock logo
APLMW
Apollomics
N/AN/AN/AN/AN/A
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
N/AN/AN/AN/AN/A
TFF Pharmaceuticals, Inc. stock logo
TFFP
TFF Pharmaceuticals
N/AN/AN/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Alvotech stock logo
ALVOW
Alvotech
N/A
Apollomics, Inc. stock logo
APLMW
Apollomics
N/A
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
N/A
TFF Pharmaceuticals, Inc. stock logo
TFFP
TFF Pharmaceuticals
15.25%

Insider Ownership

CompanyInsider Ownership
Alvotech stock logo
ALVOW
Alvotech
N/A
Apollomics, Inc. stock logo
APLMW
Apollomics
N/A
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
N/A
TFF Pharmaceuticals, Inc. stock logo
TFFP
TFF Pharmaceuticals
4.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alvotech stock logo
ALVOW
Alvotech
1,460N/AN/ANot Optionable
Apollomics, Inc. stock logo
APLMW
Apollomics
15N/AN/ANot Optionable
bioAffinity Technologies, Inc. stock logo
BIAFW
bioAffinity Technologies
57N/AN/ANot Optionable
TFF Pharmaceuticals, Inc. stock logo
TFFP
TFF Pharmaceuticals
194.44 million4.24 millionNo Data

Recent News About These Companies

TFF Pharmaceuticals Provides Regulatory Update on Tacrolimus Inhalation Powder (TFF TAC) Clinical Program for the Prevention of Lung Transplant Rejection
June 30, 2026  |  stockhouse.comhttps://stockhouse.com/news/press-releases/2024/06/24/tff-pharmaceuticals-provides-regulatory-update-on-tacrolimus-inhalation-powder
TFF Pharmaceuticals approves dissolution plan
March 8, 2025  |  uk.investing.comhttps://uk.investing.com/news/sec-filings/tff-pharmaceuticals-approves-dissolution-plan-93CH-3965207
TFF Pharmaceuticals Announces Delisting from Nasdaq and Potential SEC Deregistration
February 6, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/tff-pharmaceuticals-announces-delisting-from-nasdaq-and-potential-sec-deregistration-302370494.html
TFF Pharmaceuticals Inc (TFFP) Stock: A Deeper Look at Its True Potential
December 12, 2024  |  bovnews.comB
The TFFP Stock Mystery: Why Did TFFP Plunge Today?
December 6, 2024  |  bovnews.comB
TFF Pharmaceuticals Inc (TFFP) Stock: More Robust Than the Numbers Suggest?
November 23, 2024  |  bovnews.comB
Stock Shock: The Unpredictable Rise and Fall of TFFP—What’s Driving the Drama?
November 20, 2024  |  bovnews.comB
TFFP Unveiled: The Shocking Truth Behind TFF Pharmaceuticals Inc’s Latest Stock Movements
November 19, 2024  |  bovnews.comB
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.70%
November 15, 2024  |  msn.comhttps://www.msn.com/en-us/money/markets/u-s-stocks-lower-at-close-of-trade-dow-jones-industrial-average-down-0-70/ar-AA1uaJIC
TFF Pharmaceuticals (TFFP) Takes a Dark Turn: What’s Next for Investors?
November 15, 2024  |  bovnews.comB
TFF Pharmaceuticals Shares Fall 66%; Company to Wind Down
November 14, 2024  |  marketwatch.comhttps://www.marketwatch.com/story/tff-pharmaceuticals-shares-fall-66-company-to-wind-down-9356ffda
TFF Pharmaceuticals terminates employees, to wind down operations
November 14, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/tff-pharmaceuticals-terminates-employees-to-wind-down-operations-1034021261
TFF Pharmaceuticals to Dissolve and Liquidate Assets
November 14, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/tff-pharmaceuticals-to-dissolve-and-liquidate-assets-1034021303
TFF Pharmaceuticals, Inc. Announces Termination of Employees and Wind Down of Operations
November 14, 2024  |  quiverquant.comQ
TFF Pharmaceuticals Announces It Will Wind Down Operations
November 14, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/11/14/2981627/0/en/tff-pharmaceuticals-announces-it-will-wind-down-operations.html
TFF Pharmaceuticals (NASDAQ:TFFP) Stock Quotes, Forecast and News Summary
October 9, 2024  |  benzinga.comhttps://www.benzinga.com/quote/TFFP
TFF Pharmaceuticals (TFFP) Upgraded to Strong Buy: Here's Why
October 8, 2024  |  zacks.comhttps://www.zacks.com/stock/news/2347683/tff-pharmaceuticals-tffp-upgraded-to-strong-buy-here-s-why?cid=cs-stocknewsapi-ft-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2347683
TFF Pharmaceuticals, Inc.: TFF Pharmaceuticals' Technology Generates Superior Inhalational Dry Powder Formulations for Pulmonary Drug Delivery
September 26, 2024  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2024-09/63372214-tff-pharmaceuticals-inc-tff-pharmaceuticals-technology-generates-superior-inhalational-dry-powder-formulations-for-pulmonary-drug-delivery-399.htm
TFF Pharmaceuticals’ Technology Generates Superior Inhalational Dry Powder Formulations for Pulmonary Drug Delivery
September 26, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/tff-pharmaceuticals-technology-generates-superior-inhalational-dry-powder-formulations-for-pulmonary-drug-delivery-1033800109
Post-COVID Trends in Biopharma Contract Manufacturing
September 25, 2024  |  contractpharma.comC

Media Sentiment Over Time

Alvotech stock logo

Alvotech NASDAQ:ALVOW

$0.20 +0.06 (+42.45%)
As of 11:07 AM Eastern

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

Apollomics stock logo

Apollomics NASDAQ:APLMW

$0.01 0.00 (0.00%)
As of 09:30 AM Eastern

Apollomics, Inc., a biotechnology company, engages in the discovery and development of mono and combination oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. Its pipeline consists of various development-stage assets, including novel and humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2016 and is based in Foster City, California with additional locations in Hangzhou and Shanghai, China and Southbank, Australia.

bioAffinity Technologies stock logo

bioAffinity Technologies NASDAQ:BIAFW

$0.21 +0.06 (+40.77%)
Closing price 07:00 AM Eastern
Extended Trading
$0.21 0.00 (0.00%)
As of 07:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.

TFF Pharmaceuticals stock logo

TFF Pharmaceuticals NASDAQ:TFFP

TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment and prophylaxis of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It also develops other dry powder products, such as Augmenta human derived monoclonal antibodies for the treatment of COVID-19 disease; and other vaccines. It has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs. TFF Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Fort Worth, Texas.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas